Dr. Reddy’s Laboratories has launched Montelukast Sodium tablets in 10 mg and Montelukast Sodium Chewable tablets (4 mg & 5 mg).
The drug is a bioequivalent generic version of SINGULAIR® tablets and Chewable tablets.
The Hyderabad-based pharma major launched it in the US market on August 6, following approval by the United States Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA).
The Singular tablets and Chewable tablets brand had US sales of approximately $3.6 billion and $1.14 billion, respectively for the most recent 12 months ended March 31, 2012, according to IMS Health.
Dr. Reddy’s Montelukast Sodium tablets in 10 mg and Montelukast Sodium Chewable tablets in 4 mg and 5 mg are available in bottle counts of 30 and 90, a company release said.